Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stem cell exosome nasal spray is an investigational biologic therapy consisting of extracellular vesicles derived from stem cells, designed for the treatment of allergic rhinitis. These exosomes function as delivery vehicles for bioactive molecules, including proteins and RNAs, which exert immunomodulatory and anti-inflammatory effects on the nasal mucosa. By modulating the local immune response, the therapy aims to alleviate symptoms in patients who are refractory or poorly responsive to standard anti-allergic medications. It is currently being evaluated in a Phase 0 clinical trial (ChiCTR2400079863) sponsored by Changzhou Third People's Hospital to assess its safety and immunomodulatory impact.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stem cell exosome nasal spray.